BioSpace News Archive

Ventus Therapeutics announced today that it will host its inaugural Program Spotlight on VENT-03 on May 25th , 2023 at 11:00 AM ET.

Aytu BioPharma, Inc., a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an agreement with AMT Manufacturing Solutions, LLC, a newly established, full service Contract Manufacturing Organization, to sublease 22,909 square feet of Aytu’s Grand Prairie, TX manufacturing facility.

CG Oncology, Inc. announced updated data from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Tempus today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx . xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.

Salarius Pharmaceuticals, Inc. announces the completion of two Good Laboratory Practice toxicology studies with its targeted protein degrader SP-3164, with no unexpected safety findings during the course of either study.

Evoke Pharma, Inc. (NASDAQ: EVOK) announced that its recently issued U.S. patent related to GIMOTI, No. 11,628,150 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the “Orange Book”.

Neuronetics, Inc. announced the addition of Lisa Metzner-Rosas to the Company’s senior leadership team in the role of Senior Vice President, Chief Marketing Officer, effective May 1, 2023.

sanofi-aventis Canada Inc. (Sanofi Canada) is pleased to announce that Health Canada has issued a Notice of Compliance (“NOC”) for Libtayo® (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC).

On May 6, 2023, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to ‘Step Towards the Cures, Together’ at their 8th Annual Walk ‘n’ Wheel for LGS Research.